Name: Fibromyalgia: A Real Central-Pain Disorder, Managed by Exercise Not Cured by a Supplement
Creator: Realised
Published: 2026-06-01

Summary

Fibromyalgia is a genuine central-sensitisation (nociplastic) pain disorder with objective CNS signatures — not faking, not just depression — and the best-evidenced management is a bundle led by graded, self-paced aerobic and strength exercise (the single strongest lever and the only therapy the European guideline rates "strong for"), supported by sleep work, CBT and pain-neuroscience education, with modest-benefit drugs (duloxetine, pregabalin, milnacipran, low-dose amitriptyline) that help roughly one in six to ten people; it is over-claimed in both directions at once — dismissed as "not rea

Why Moderate

Moderate. The entry's spine is well-supported but the load-bearing management claims rest mostly on moderate-certainty evidence with modest effect sizes: a Cochrane review at moderate certainty for exercise's effect on well-being/HRQL (low for physical function, pain, fatigue and stiffness), moderate-to-good certainty for the small drug NNTs, and a Cochrane finding of a small CBT effect. The mechanism claim (central sensitisation, nociplastic pain) is itself strong consensus, and the against-opioid and against-fringe-cure conclusions are firmly grounded, but the therapeutic headline — how much these levers move the condition — is genuinely modest and mostly low-to-moderate GRADE. Rating the whole entry at the mechanism's strength would overstate the management evidence and reproduce the over-claim the entry exists to debunk.

NOT Strong because the therapeutic effect sizes are small and the certainty for the management levers is predominantly low-to-moderate; the benefit is real but bounded.

NOT Emerging because the direction of the evidence is settled and convergent (exercise-first, opioids-out, no-supplement-cure), backed by Cochrane reviews, a specialty guideline (EULAR) and IASP consensus — not a scattering of suggestive studies.

The per-claim split (read this, not just the headline):
• It is a real central-sensitisation / nociplastic disorder: Strong (consensus mechanism, imaging literature).
• Graded exercise as the strongest lever: Moderate (Cochrane, moderate certainty for well-being/HRQL, low for physical function and pain).
• Modest drug benefit (NNT ~6–10): Moderate.
• CBT / pain-neuroscience education: Moderate to Emerging (small effect).
• Opioids do not work and harm: Strong for the against-opioid conclusion.
• No supplement/detox/"chronic Lyme or mold" cure: Strong debunk; the fringe claims themselves are experimental-to-absent.

Practical takeaway

The framing to hold: your pain is real and it is a nervous-system amplification problem, not a moral failing or an imaginary one. It is manageable but not curable by a single act. The levers genuinely help, the gains are modest, and the biggest one is movement done gently and consistently.

Lead with graded, self-paced exercise (the strongest lever).
• Start well below what feels like a challenge and build slowly; the goal is consistency, not intensity. A flare after over-doing it is information about pacing, not proof that movement is harmful.
• Both aerobic and strength work help; pick what you can sustain. Warm-water/aquatic and low-impact options suit many people early on.
• The mood and dose-response side of exercise is owned by exercise_for_mood_dose_response; use it for how much and how hard.
• Important boundary: where post-exertional malaise dominates — symptoms reliably crash for a day or more after activity — this may be an ME-CFS-overlap picture where standard graded-exercise advice can HARM. Do not force the exercise message onto that presentation; see chronic_infections_and_postviral_syndromes.

Rebuild sleep. Non-restorative sleep both results from and feeds fibromyalgia. Behavioural sleep restoration (CBT for insomnia) is the evidence-based route and is owned by cbt_i_program_overview.

Add CBT and pain-neuroscience education as supportive layers. Understanding that the pain is real and that it reflects an over-sensitised system (not ongoing tissue damage) reduces fear-avoidance and, combined with exercise, gives a small real benefit. Framed as support, not cure.

Treat drugs as a modest, optional adjunct. Duloxetine, pregabalin, milnacipran or low-dose amitriptyline are reasonable to trial with a clinician. Set expectations honestly: they meaningfully help a minority. If a drug does nothing after a fair trial, that is the expected outcome for most people, not a personal failure.

Do not go near the fringe cures.
• No supplement stack, detox, cleanse, antibiotic or antifungal course cures fibromyalgia. Money spent there buys hope, side-effects and delay.
• Be wary of clinics reframing fibromyalgia as "chronic Lyme," "mold toxicity," "heavy-metal toxicity" or "mitochondrial dysfunction" to justify long, expensive, cash-pay treatment. There is no evidence a persistent infection or toxin is the cause.

Never route the pain to opioids. They do not work for this condition and make function, sleep and mood worse. This is one place to hold the line.

Evidence detail

Why This Entry Exists

Fibromyalgia sits in a rare double bind: it is disbelieved and over-promised in the same breath, and both errors hurt patients. The first error is dismissal. Because there is no swollen joint to point at and no blood test that clinches it, fibromyalgia gets waved off as malingering, attention-seeking, or "just your depression talking." That framing is contradicted by the imaging and by the plain fact that the evidence-based levers actually work on it. The second error is the mirror image: an entire cash-pay economy of supplement stacks, detox protocols, and "chronic Lyme" or "mold toxicity" clinics sells expensive, unproven, sometimes harmful courses on the promise of a cure. There is no cure to sell. So a person with fibromyalgia is squeezed between being told their pain is imaginary and being told it can be fixed by the right cleanse, and neither is true.

This entry holds the honest middle. Fibromyalgia is a real central-sensitisation disorder: the nervous system amplifies pain signalling and loses some of its own braking, and this shows up on functional imaging. The levers that genuinely help are modest and unglamorous — graded exercise first, then sleep, CBT and pain education, then drugs that help some people some of the amount. None of them is a cure, and saying otherwise reproduces the same over-claim the fringe trades on. The message a person needs is: your pain is real, these levers genuinely move it, the gains are real but modest, and no single act — no pill, no supplement, no detox — makes it go away.

What bad advice this protects against, in all directions:
• "It's not real / it's all in your head / it's just depression" → central sensitisation is measurable on functional imaging and the evidence-based levers work on it; dismissal is both wrong and harmful, and it delays the management that actually helps.
• "Just push through it — exercise is the cure" → exercise is the strongest lever, but it must be graded and self-paced; pushing too hard flares symptoms and replicates the exact harm patients already fear. It is management, not cure.
• "A supplement / detox / gut-cleanse protocol will cure your fibromyalgia" → no supplement, detox, antibiotic or antifungal course has controlled evidence of curing it; this is where the commercial over-claim concentrates.
• "Your fibromyalgia is really chronic Lyme (or mold toxicity)" → there is no evidence a persistent infection or environmental toxin causes it, and the symptoms attributed to "chronic Lyme" are in many cases fibromyalgia itself; the long antibiotic/antifungal/chelation courses sold on that label are unsupported and can harm.
• "Get on an opioid for the pain" → opioids (including tramadol) show no efficacy for fibromyalgia and are linked to worse function, worse sleep, worse mood and a sharp rise in opioid-use disorder; the guideline recommends against them.
• "The drugs will fix it" → duloxetine, pregabalin and milnacipran help only about one in six to ten people reach meaningful pain relief; worth trying, not magic, and not a substitute for exercise and self-management.

This entry owns the it-is-real framing and the best-evidenced-management bundle for fibromyalgia. It defers exercise-for-mood dosing to exercise_for_mood_dose_response, the sleep-restoration programme to cbt_i_program_overview, and the post-viral / ME-CFS overlap — where a graded-exercise message can actively harm — to chronic_infections_and_postviral_syndromes. It states those boundaries and routes there rather than re-arguing them.

Evidence

Organised by claim, with the tier signal inline. The headline management bundle is well-supported, but effect sizes are modest and certainty is mostly low-to-moderate — read the tiers, not just the thesis.

1. Fibromyalgia is a central-sensitisation / nociplastic-pain disorder with objective CNS signatures (Strong Evidence for the mechanism). Fibromyalgia is the prototype of nociplastic pain — pain arising from altered central processing rather than tissue damage or nerve injury — a category the International Association for the Study of Pain formalised in 2017. The mechanism combines augmented ascending nociceptive signalling with reduced descending inhibition, and functional MRI shows augmented pain processing (first demonstrated by Clauw's group in 2002) with altered connectivity across the default-mode, salience and sensorimotor networks. This is the anchor for the "it is real, not faking, not just depression" framing. (Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. "Nociplastic pain: towards an understanding of prevalent pain conditions." Lancet 2021;397:2098–2110; nociplastic-pain category formalised by IASP 2017. Tier signal — authoritative narrative review plus a mechanistic imaging literature; the mechanism is well-established consensus, though the biomarker is not yet clinically diagnostic.)

2. Graded aerobic exercise is the strongest lever — moderate-quality benefit for well-being and function (Moderate Evidence). A Cochrane review of 13 RCTs (839 participants) found moderate-certainty evidence that aerobic exercise improves global well-being / health-related quality of life (mean difference about -7.9 on a 0–100 scale, 95% CI -13.2 to -2.6) and low-certainty evidence for improved physical function (MD about -10.2, 95% CI -15.4 to -4.9) and for reduced pain, fatigue and stiffness, with dropout similar to control — i.e. it is tolerable. This is the evidence base behind the European League Against Rheumatism (EULAR) making exercise the only therapy rated "strong for" in its revised recommendations. (Bidonde J, Busch AJ, Schachter CL, et al. "Aerobic exercise training for adults with fibromyalgia." Cochrane Database Syst Rev 2017, CD012700. Macfarlane GJ, Kronisch C, Dean LE, et al. "EULAR revised recommendations for the management of fibromyalgia." Ann Rheum Dis 2017;76:318–328. Tier signal — Cochrane systematic review, moderate certainty for well-being/function and low for pain, with GRADE downgrades for bias; genuine but modest.)

3. Drugs help modestly, not miraculously (Moderate Evidence). For a clinically meaningful ≥30% pain reduction, the number-needed-to-treat is roughly 6 to 10 for duloxetine, pregabalin and milnacipran; for the stricter ≥50% reduction only about one in ten patients benefits (NNT ~7–14). Low-dose amitriptyline is a reasonable option but the evidence is low-quality. In plain terms: worth trying, and it changes some lives, but most people are not the responder. (Cochrane overview of pharmacological therapies for fibromyalgia, Rheumatology (Oxford) 2025; Cochrane pregabalin review CD011790; Lunn MPT, Hughes RAC, Wiffen PJ. "Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia." Cochrane Database Syst Rev 2014, CD007115.pub3; network meta-analysis of amitriptyline/duloxetine/pregabalin, 2022. Tier signal — moderate-to-good certainty for duloxetine/pregabalin/milnacipran, lower for amitriptyline; effect real but small.)

4. Opioids do NOT work for fibromyalgia and cause net harm (Strong Evidence for the against-opioid conclusion). There is no RCT evidence of opioid efficacy in fibromyalgia. A 12-month observational cohort found opioid users did no better on pain and worse on function, insomnia, disability and depression than non-users; opioid use in fibromyalgia has been linked to a roughly 12-fold rise in opioid-use-disorder hospitalisations over 1998–2014. EULAR 2017 recommends against strong opioids, and the tramadol evidence is weak with toxicity concerns. In a central-pain state, opioids can drive hyperalgesia — making the underlying problem worse. (Mayo Clinic Proceedings 2016, "Opioid Use in Fibromyalgia: A Cautionary Tale"; Macfarlane GJ, et al., EULAR revised recommendations 2017, Ann Rheum Dis 2017;76:318–328. Tier signal — convergent guideline, observational and mechanistic evidence with no efficacy signal; this conclusion is now mainstream, CDC- and EULAR-aligned.)

5. The "it's secretly chronic Lyme / mold toxicity" route is a fringe misdiagnosis engine (Strong Evidence for the debunk; essentially no evidence for the fringe claim). There is no evidence that any persistent infection causes "chronic Lyme disease," and the symptoms attributed to it are in many cases fibromyalgia or chronic fatigue syndrome. Clinics attach unsupported labels — heavy-metal toxicity, mitochondrial dysfunction, immune dysfunction — to justify long antibiotic, antifungal, chelation and supplement courses. No supplement or detox protocol has RCT evidence of curing fibromyalgia. (Feder HM Jr, Johnson BJB, O'Connell S, et al. "A critical appraisal of 'chronic Lyme disease'." N Engl J Med 2007;357:1422–1430; scientific consensus per IDSA/CDC. Tier signal — the debunk is well-grounded; the miracle cures sit at experimental-to-absent, with essentially no controlled evidence.)

6. CBT and pain-neuroscience education give small-but-real incremental benefit, not a cure (Moderate to Emerging Evidence). A Cochrane review found CBT reduced pain by roughly 0.5 points out of 10 at end of treatment and ~0.6/10 at long-term follow-up over controls — small but real. Pain-neuroscience education (PNE) shows low-to-moderate certainty for reduced pain and impact, strongest when delivered face-to-face and combined with exercise, as in the FIBROWALK multicomponent RCT. These are supportive levers layered onto exercise, not standalone fixes. (Bernardy K, Klose P, Busch AJ, Choy EHS, Häuser W. Cochrane CBT for fibromyalgia, CD009796; systematic review/meta-analysis of pain-neuroscience education, 2022; Serrat M, et al. "Effectiveness of the FIBROWALK multicomponent program." Phys Ther 2021;101:pzab200. Tier signal — Cochrane CBT finding moderate certainty for a small effect; PNE low-to-moderate certainty.)

Mechanism

This entry owns the it-is-real mechanism and the management rationale, not the full physiology of every adjacent condition. Enough mechanism here to make the framing and the ceiling intelligible; the exercise-mood dose-response is deferred to exercise_for_mood_dose_response, sleep restoration to cbt_i_program_overview, and the post-viral overlap to chronic_infections_and_postviral_syndromes.

Why it is a real disorder and not "in the head." Fibromyalgia is nociplastic pain: the problem is in how the central nervous system processes pain, not in a damaged joint or nerve. Two things are altered together — the ascending signal is amplified (a normal touch is read as painful, the volume knob is turned up), and the descending inhibition that should dampen pain is weakened (the brakes are worn). Functional MRI shows augmented pain processing to standardised stimuli and altered network connectivity. That objective CNS signature is why "you're faking" and "it's just depression" are wrong: depression can coexist and worsen the picture, but the central pain amplification is its own measurable phenomenon.

Why exercise is the strongest lever. Graded aerobic and strength exercise appears to act on the same central machinery — improving descending pain modulation and, over time, reducing the sensitisation — while also breaking the deconditioning-and-fear-avoidance spiral that intensifies symptoms. The catch is dose. Too much, too soon flares symptoms, which teaches the patient (reasonably) that movement hurts and drives them back to rest. Self-paced, gradually escalating load is what separates the benefit from the harm, which is why the guideline language is "graded," not "exercise."

Why the drugs help only some people. Duloxetine and milnacipran raise noradrenaline and serotonin to reinforce the weakened descending inhibition; pregabalin damps overactive ascending signalling. These are real mechanisms, but they engage only part of a distributed problem, in only part of the population — hence NNTs around six to ten and a majority who are non-responders. They are adjuncts to self-management, not the treatment.

Why opioids make a central-pain state worse. Opioids can induce hyperalgesia and disrupt the same descending systems fibromyalgia already has trouble with, so in this specific disorder they add tolerance, dependence and functional decline without touching the driver. That is the mechanistic reason the observational data show opioid users doing worse, not better.

Risks And Contraindications

• The two-directional tone risk is the main hazard. Do not let the honest "drugs and CBT are only modestly effective, and the certainty is low-to-moderate" framing slide into the dismissive "it's not real" camp. The mechanistic reality — central sensitisation, altered fMRI processing — is the anchor and must lead. Equally, do not let "exercise is the strongest lever" harden into a stick; deconditioning and post-exertional flares are real and pushing too hard replicates the harm patients fear.
• Exercise must be graded and self-paced. A generic "just get more active" instruction can cause a symptom flare and entrench avoidance. Pacing and gradual escalation are load-bearing, not optional detail.
• The post-viral / ME-CFS overlap can invert the exercise advice. Where post-exertional malaise dominates, standard graded-exercise-therapy guidance can HARM. This entry must not over-generalise its exercise message onto that population — defer to chronic_infections_and_postviral_syndromes.
• Do not overstate the effect sizes. Most of the benefit sits at low-to-moderate GRADE certainty with modest magnitudes; overstating it reproduces the same over-claim the entry debunks.
• The "chronic Lyme / mold" debunk targets the commercial pipeline, not the patient. Many people arrive with these labels because they were routed there by a clinic; the debunk is of the misdiagnosis machinery, never a mockery of the patient.
• Red-flag boundary — make sure it is actually fibromyalgia. Fibromyalgia is a clinical diagnosis of central pain without tissue damage. Features that point AWAY from it and warrant medical assessment for another cause include: an objectively swollen, hot joint (inflammatory arthritis or infection), unexplained weight loss, fever or night sweats, a new focal neurological deficit, or markedly abnormal inflammatory markers. These belong to a clinician, not to lifestyle self-management. Because depression and anxiety commonly co-occur, any thoughts of self-harm or suicide are an urgent medical matter, not a symptom to manage at home.

Controversy

Nature: a genuinely real central-pain disorder with a modest, well-evidenced management bundle, caught between two opposing over-claims — outright dismissal ("not real / just depression") on one pole, and miracle-cure marketing ("supplement / detox it away," "it's secretly chronic Lyme or mold") on the other — with a separate, settled sub-controversy (opioids) resolved firmly against use.

Position A — "Fibromyalgia is real and the evidence-based levers genuinely help." The accurate take.
• Best evidence: reproducible CNS signatures (augmented ascending signalling, reduced descending inhibition, altered fMRI processing) establish it as a nociplastic disorder; graded exercise carries moderate-quality benefit and is EULAR's only "strong for" therapy; sleep, CBT and pain education add small real gains; duloxetine/pregabalin/milnacipran help a minority.
• Where it goes wrong if overstated: it tips into "exercise (or a drug) cures it," or into an unpaced "just push through" that flares symptoms.

Position B — "It's over-claimed and mostly unfixable, so beware the cures." The corrective take.
• Best evidence: effect sizes are modest and mostly low-to-moderate certainty; no supplement, detox, antibiotic or antifungal protocol has RCT evidence of a cure; "chronic Lyme"/mold explanations have no supporting evidence and the symptoms are often fibromyalgia itself; opioids show no efficacy and cause net harm.
• Where it goes wrong if overstated: it can slide into "nothing works / it's not real," which strips patients of the genuine, modest help that exists and re-stigmatises them.

The funding/bias dimension — cui bono, both ways. Toward over-claiming benefit: the pivotal drug-efficacy trials were largely industry-sponsored (Eli Lilly for duloxetine, Pfizer for pregabalin), a pro-drug, publication-bias lean; and the functional-medicine / "chronic Lyme" / mold-clinic economy profits directly from long cash-pay courses and supplement sales. Toward the corrective pole: the strongest anchors are conflict-clean — the independent Cochrane overviews report the small NNTs and act as the correction to the sponsor trials, EULAR and IASP consensus are non-commercial, and the anti-opioid position runs against the historical opioid-marketing interest, which strengthens it. The single strongest recommendation — exercise — has nobody selling it, which is partly why it is under-marketed relative to pills and supplements.

Realised Position: Fibromyalgia is real and manageable but not curable by any single act. The recovery levers are legitimate and modest: graded, self-paced exercise is the foundation, sleep and CBT/pain-education are supportive, and drugs help roughly one in six to ten people — worth trying, not magic. Realised actively debunks both the "not real" dismissal and the supplement/detox/"it's really Lyme or mold" upsell, and it never routes fibromyalgia pain to opioids. This is a spine-management posture: return toward baseline function, not chase a cure.

Cross-Pillar Connections

Fibromyalgia is a genuinely cross-pillar topic — the levers span movement, sleep, mental health and evidence-literacy, and the condition overlaps with post-viral fatigue.
• Physical / Mental (exercise_for_mood_dose_response): owns the exercise dose-response and its mood effects; this entry holds only that graded, self-paced exercise is the strongest lever for fibromyalgia and defers the dosing there.
• Sleep (cbt_i_program_overview): owns the behavioural sleep-restoration programme; this entry holds only that rebuilding non-restorative sleep is a supportive lever and routes there for the method.
• Conditions (chronic_infections_and_postviral_syndromes): owns the post-viral / ME-CFS picture where post-exertional malaise dominates and graded-exercise advice can HARM; this entry flags the overlap and hands off rather than over-generalising its exercise message.
• Conditions (histamine_intolerance_and_mast_cell_activation): a neighbouring contested-cause label that patients are frequently routed into alongside fibromyalgia; relevant to the both-ways over-claim this entry debunks.
• Foundations / Method (publication_bias_and_evidence_distortion): the sponsor-funded efficacy trials versus independent Cochrane corrections are a textbook case of why the entry cites the reviews, not the trials.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd reopen "not curable by a pill or a cleanse" if a large, well-conducted RCT showed a supplement, detox, antibiotic or antifungal protocol actually cures or substantially resolves fibromyalgia (not just short-term symptom flutter). None exists.
• We'd upgrade "secretly Lyme/mold" from fringe to a legitimate subtype if robust evidence showed a persistent infection or environmental toxin CAUSES fibromyalgia in a defined subgroup.
• We'd soften the anti-opioid stance on a high-quality trial showing opioids produce durable benefit without net functional or harm cost.
• We'd raise the drug tier on head-to-head evidence that a drug delivers large benefit (not NNT ~6–10) rather than help-a-minority benefit.
• We'd lower the exercise claim if evidence showed its effects are largely placebo/expectancy once blinding and attrition are properly handled — current Cochrane certainty is only low-to-moderate, so this is a live, watch-this-space caveat rather than settled fact.

Industry bias note

Structural incentives the evidence base may reflect

Cui bono runs in two opposing directions, and the conflict-clean sources sit in the middle.
• Pharma funded the efficacy trials — a pro-drug lean. The pivotal duloxetine (Eli Lilly) and pregabalin (Pfizer) trials were largely industry-sponsored, with the attendant publication-bias risk. The correction is the independent Cochrane syntheses, which report the small NNTs — so the entry cites the reviews, not the sponsor trials, and states the benefit as help-a-minority rather than the trials' more flattering framing.
• The fringe economy profits from cash-pay misdiagnosis. Functional-medicine practices and "chronic Lyme"/mold clinics have a direct financial stake in relabelling fibromyalgia and selling long antibiotic, antifungal, chelation and supplement courses. This is the clearest financial-conflict axis in the topic, and the entry names it explicitly rather than treating the fringe cures as merely "unproven."
• The strongest recommendation has nobody selling it. Exercise is unmonetised, which is precisely why it is under-marketed relative to drugs and supplements despite being the only "strong for" therapy. The independently funded consensus (Cochrane, EULAR, IASP) is the conflict-clean anchor.
• The anti-opioid position runs against the money. Historical opioid-marketing interest ran toward prescribing; the current CDC/EULAR-aligned against-opioid consensus runs against that money, which strengthens its credibility. Net: the load-bearing claims are publicly funded or independent and cut against sellers in both directions.

Fibromyalgia: A Real Central-Pain Disorder, Managed by Exercise Not Cured by a Supplement